IgG4
Recent data from Kiszel et al (2023) provide evidence that IgG4 is a major mediator of mRNA vaccine-induce autoimmune disease. The most abundant antibody (also called immunoglobulin) isotype in the human serum (blood is different from mucosa where IgA dominates) is immunoglobulin G (IgG). The subclasses of IgG are very similar but differ in their constant regions (the region of antibody used to destroy antigens). Each subclass has a unique profile in terms of antigen binding, immune complex formation, complement activation and triggering of effector cell activation. After antigenic stimuli, IgG3 and IgG1, the two main complement-activating subclasses are secreted first, whereas IgG2 and IgG4, which are formed later, are thought to play a role in attenuating inflammation due to their inability to activate complement. Previous studies have found that antibody responses to viral protein antigens are mainly restricted to IgG1 and IgG3. IgG2 is stimulated primarily by carbohydrate antigens, whereas IgG4 is produced in response to helminthic (parasitic worms) infections or to, very importantly to mechanisms of action in mRNA vaccine injury, prolonged antigen stimulations. mRNA vaccination yields a higher antibody titer than does the SARS-CoV-2 infection. In other words, a huge amount of antigen presentation elicited by the mRNA vaccination induces a huge amount of antibody production – too much. That huge antibody production means a high level of autoantibodies, such as IgG4.
IgG4 can mediate autoimmune diseases and create gut dysbiosis and leaky gut (Wang et al, 2018), potentially leading to a number of maladies. However, IgG subclasses produced against protein antigens depend on factors other than the type of pathogens or type of vaccine, such as T-helper cell response, and the route and the site of infections or injections. As such, the intricacies of how an individual will respond to a particular vaccine is largely unknown. The drug companies don’t want to know because their business model is to give a drug to as many people as possible, and knowing about injuries is an impediment to making money. Leave it to academic researchers who aren’t paid-off by pharma to figure out the safety data. Alas, there is not enough money in academia to do this well, but Kiszel et al (2023) give us important info.
Let’s look at what mRNA vaccines do to the different antibody levels. Here’s Figure 5 from Kiszel et al (2023).